World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
65
Citations
34396
World Ranking
8928
National Ranking
274

Jifeng Feng publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Jifeng Feng sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 421 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Jifeng Feng D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Jifeng Feng sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 65 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Jifeng Feng is affiliated with Nanjing Medical University in China. Their research work spans broadly across the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology and Pulmonary and Respiratory Medicine. Subfields of study include Molecular Biology, Cancer Research, and Pathology and Forensic Medicine.

The scientist's research primarily addresses topics related to Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Advanced Breast Cancer Therapies, Lymphoma Diagnosis and Treatment, Colorectal Cancer Treatments and Studies, and HER2/EGFR in Cancer Research.

Frequent publication venues for Jifeng Feng include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Research Square (Research Square)
  • Frontiers in Oncology
  • Journal of Thoracic Oncology

Among the recent papers featuring Jifeng Feng's research are:

  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial, 2020, The Lancet Respiratory Medicine
  • Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11), 2020, Journal of Thoracic Oncology
  • Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02), 2021, Journal of Clinical Oncology
  • AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations, 2022, Journal of Clinical Oncology

Collaborations form a significant part of their work, with frequent coauthors including Jian Wu, Ying Cheng, Qingyuan Zhang, Jianying Zhou, and Yuankai Shi.

Best Publications

  • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

    Ann Lii Cheng;Yoon Koo Kang;Zhendong Chen;Chao Jung Tsao

  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

    Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

    Yi-Long Wu;Caicun Zhou;Cheng-Ping Hu;Jifeng Feng

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

    Yuankai Shi;Li Zhang;Xiaoqing Liu;Caicun Zhou

  • Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

    Jonathan W Goldman;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial

    Huiyan Luo;Huiyan Luo;Jin Lu;Yuxian Bai;Teng Mao

  • BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

    Caicun Zhou;Yi-Long Wu;Gongyan Chen;Xiaoqing Liu

  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

    Caicun Zhou;Gongyan Chen;Yunchao Huang;Jianying Zhou

  • Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

    Fei Ma;Quchang Ouyang;Wei Li;Zefei Jiang

  • Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).

    Yunpeng Yang;Zhehai Wang;Jian Fang;Qitao Yu

  • Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

    Binghe Xu;Min Yan;Fei Ma;Xichun Hu

  • Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.

    Yi Long Wu;Shun Lu;Ying Cheng;Caicun Zhou

  • Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Zefei Jiang;Wei Li;Xichun Hu;Qingyuan Zhang

  • Tumor-derived exosomes in cancer progression and treatment failure

    Shaorong Yu;Haixia Cao;Bo Shen;Jifeng Feng

  • Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).

    Feng-Hua Wang;Xiao-Li Wei;Jifeng Feng;Qi Li

  • Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin.

    Xia Xiao;Shaorong Yu;Shuchun Li;Jianzhong Wu

  • Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.

    Xiaobing Qin;Shaorong Yu;Leilei Zhou;Meiqi Shi

Frequent Co-Authors

Caicun Zhou
Caicun Zhou Tongji University
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Li Zhang
Li Zhang Sun Yat-sen University
Yongqian Shu
Yongqian Shu Nanjing Medical University
Igor Bondarenko
Igor Bondarenko Ministry of Internal Affairs
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Tony Mok
Tony Mok Chinese University of Hong Kong
Lecia V. Sequist
Lecia V. Sequist Harvard University
Wu Chou Su
Wu Chou Su National Cheng Kung University
Rui-Hua Xu
Rui-Hua Xu Sun Yat-sen University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Biology and Biochemistry in the USA can lead to diverse and rewarding career opportunities, many of which can be furthered with online education. For those interested in mental health, psychiatric np programs offer a fast, flexible route to advanced nursing roles focused on psychiatric care.

If you’re passionate about health and wellness, earning a fast track nutrition degree can help position you for roles in clinical nutrition, public health, or wellness coaching. Online programs allow you to complete coursework at your own pace, often accelerating your entry into the workforce.

For students drawn to the business side of healthcare, an affordable online mba in healthcare management can open doors to leadership positions in hospitals, clinics, and biotech companies. These practical MBA programs are ideal for working professionals seeking advancement.

Lastly, those considering careers in medical coding and administration can compare ccs vs cpc certifications. Understanding the differences between these credentials can help you choose the right certification for your career goals and salary expectations in healthcare administration.

Best Scientists Citing Jifeng Feng

Trending Scientists

Recently Published Articles